Total Payments
$314.34
2024 Payments
$45.71
Companies
11
Transactions
19
Medicare Patients
9,166
Medicare Billing
$507,151
Payment Breakdown by Category
Food & Beverage$282.13 (89.8%)
Education$32.21 (10.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $282.13 | 14 | 89.8% |
| Education | $32.21 | 5 | 10.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $113.93 | 5 | $0 (2023) |
| United Therapeutics Corporation | $32.21 | 5 | $0 (2021) |
| HEARTFLOW, INC. | $24.67 | 1 | $0 (2024) |
| Novo Nordisk Inc | $24.52 | 1 | $0 (2023) |
| Amgen Inc. | $21.04 | 1 | $0 (2024) |
| Sandoz Inc. | $20.56 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $20.24 | 1 | $0 (2022) |
| Allergan Inc. | $18.20 | 1 | $0 (2017) |
| PFIZER INC. | $14.41 | 1 | $0 (2019) |
| Gilead Sciences Inc | $13.26 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45.71 | 2 | HEARTFLOW, INC. ($24.67) |
| 2023 | $72.81 | 3 | Daiichi Sankyo Inc. ($27.73) |
| 2022 | $20.24 | 1 | Novartis Pharmaceuticals Corporation ($20.24) |
| 2021 | $32.21 | 5 | United Therapeutics Corporation ($32.21) |
| 2019 | $37.66 | 2 | Daiichi Sankyo Inc. ($23.25) |
| 2018 | $11.30 | 1 | Kowa Pharmaceuticals America, Inc. ($11.30) |
| 2017 | $94.41 | 5 | Daiichi Sankyo Inc. ($62.95) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/20/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $24.67 | General |
| Category: Coronary | ||||||
| 02/14/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Cardiology | ||||||
| 12/12/2023 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Diabetes | ||||||
| 11/03/2023 | Sandoz Inc. | TREPROSTINIL (Drug) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: PULMONARY ARTERIAL HYPERTENSION | ||||||
| 09/15/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $27.73 | General |
| Category: Iron Deficiency Anemia | ||||||
| 05/23/2022 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/08/2021 | United Therapeutics Corporation | — | Education | In-kind items and services | $2.50 | General |
| 08/24/2021 | United Therapeutics Corporation | REMODULIN (Drug) | Education | In-kind items and services | $2.50 | General |
| Category: PAH | ||||||
| 06/17/2021 | United Therapeutics Corporation | ORENITRAM (Drug) | Education | In-kind items and services | $22.21 | General |
| Category: PAH | ||||||
| 06/09/2021 | United Therapeutics Corporation | — | Education | In-kind items and services | $2.50 | General |
| 04/29/2021 | United Therapeutics Corporation | REMODULIN (Drug) | Education | In-kind items and services | $2.50 | General |
| Category: PAH | ||||||
| 10/25/2019 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/31/2019 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: Anemia | ||||||
| 02/16/2018 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Vascepa | Food and Beverage | Cash or cash equivalent | $11.30 | General |
| Category: Cardiovascular | ||||||
| 10/17/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $23.74 | General |
| Category: Anemia | ||||||
| 08/28/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $24.66 | General |
| Category: Anemia | ||||||
| 05/12/2017 | Allergan Inc. | BYSTOLIC (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/24/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $13.26 | General |
| 01/20/2017 | Daiichi Sankyo Inc. | Effient (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Thrombosis | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 1,589 | 1,900 | $629,273 | $76,189 |
| 2022 | 32 | 2,673 | 3,511 | $1.1M | $144,034 |
| 2021 | 30 | 2,328 | 3,234 | $984,707 | $143,961 |
| 2020 | 29 | 2,576 | 3,560 | $953,962 | $142,966 |
Total Patients
9,166
Total Services
12,205
Medicare Billing
$507,151
Procedure Codes
130
All Medicare Procedures & Services
130 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 210 | 273 | $106,125 | $19,133 | 18.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 188 | 188 | $95,100 | $8,438 | 8.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 57 | 57 | $96,862 | $7,407 | 7.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 24 | 24 | $71,166 | $7,389 | 10.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 42 | $15,795 | $3,790 | 24.0% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 19 | 76 | $10,828 | $3,550 | 32.8% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 22 | 34 | $4,855 | $3,192 | 65.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 24 | $17,564 | $3,157 | 18.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 59 | 59 | $29,146 | $3,022 | 10.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 23 | $12,065 | $2,861 | 23.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 282 | 284 | $38,546 | $2,492 | 6.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 274 | 375 | $25,717 | $2,162 | 8.4% |
| Q9956 | Injection, octafluoropropane microspheres, per ml | Office | 2023 | 23 | 69 | $9,174 | $1,779 | 19.4% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 15 | 15 | $14,567 | $1,224 | 8.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 25 | 25 | $15,096 | $1,024 | 6.8% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 12 | 12 | $12,224 | $895.73 | 7.3% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 54 | 54 | $9,504 | $791.96 | 8.3% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Facility | 2023 | 12 | 12 | $8,232 | $719.34 | 8.7% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 54 | 54 | $6,156 | $525.28 | 8.5% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 21 | 23 | $4,715 | $438.38 | 9.3% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Office | 2023 | 23 | 23 | $4,899 | $325.91 | 6.7% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Facility | 2023 | 12 | 12 | $1,633 | $320.97 | 19.7% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 17 | 17 | $3,303 | $305.66 | 9.3% |
| 93272 | Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | Facility | 2023 | 16 | 16 | $4,086 | $296.20 | 7.2% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 21 | 21 | $3,120 | $286.65 | 9.2% |
About Dr. David Groden, M.D
Dr. David Groden, M.D is a Cardiovascular Disease healthcare provider based in Brookfield, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275575276.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Groden, M.D has received a total of $314.34 in payments from pharmaceutical and medical device companies, with $45.71 received in 2024. These payments were reported across 19 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($282.13).
As a Medicare-enrolled provider, Groden has provided services to 9,166 Medicare beneficiaries, totaling 12,205 services with total Medicare billing of $507,151. Data is available for 4 years (2020–2023), covering 130 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Brookfield, WI
- Active Since 06/12/2006
- Last Updated 09/15/2015
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1275575276
Products in Payments
- INJECTAFER (Drug) $99.38
- FFRct (Device) $24.67
- Ozempic (Drug) $24.52
- ORENITRAM (Drug) $22.21
- Repatha (Biological) $21.04
- TREPROSTINIL (Drug) $20.56
- LEQVIO (Drug) $20.24
- BYSTOLIC (Drug) $18.20
- Effient (Drug) $14.55
- ELIQUIS (Drug) $14.41
- Livalo (Drug) $11.30
- REMODULIN (Drug) $5.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Brookfield
Ramagopal Tumuluri, Md, MD
Cardiovascular Disease — Payments: $7,760
Cardiovascular Disease $7,760
Dr. Daniel Hemsworth, Md, MD
Cardiovascular Disease — Payments: $4,830
Cardiovascular Disease $4,830
Dr. Robert Ninneman, Md, MD
Cardiovascular Disease
Cardiovascular Disease
Dr. Lisa Baratta, Md, MD
Cardiovascular Disease
Cardiovascular Disease
Dr. Timothy Hess, M.d, M.D
Cardiovascular Disease
Cardiovascular Disease